BSN Medical en route to independent growth
This article was originally published in Clinica
Executive Summary
Three months after inking the euro1bn ($1.2bn) deal, UK orthopaedics firm Smith & Nephew and German consumer products group Beiersdorf have completed the sale of their 50:50 joint venture, BSN Medical, to European investment firm Montagu Private Equity. And with all ties cut loose from its previous shareholders, BSN intends to fully capitalise on its newfound independence and pursue its growth objectives at full throttle.
You may also be interested in...
BSN medical Investment Pays Off For EQT In €2.7bn Deal
BSN medical is changing owners for the third time in a decade, with a multi-billion-euro deal that will see the wound-care and orthopedics specialist enter the folds of SCA, a Swedish group that sells consumer health-care products, among other things.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.